Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial - ECOG-ACRIN EA6134J. Clin. Oncol 2022 Sep 27;[EPub Ahead of Print], MB Atkins, SJ Lee, B Chmielowski, AA Tarhini, GI Cohen, TG Truong, HH Moon, D Davar, M O'Rourke, JJ Stephenson, BD Curti, WJ Urba, JM Brell, P Funchain, KL Kendra, AP Ikeguchi, A Jaslowski, CL Bane, MA Taylor, M Bajaj, RM Conry, RJ Ellis, TF Logan, N Laudi, JA Sosman, DG Crockett, AL Pecora, IJ Okazaki, S Reganti, S Chandra, S Guild, HX Chen, HZ Streicher, JD Wolchok, A Ribas, JM Kirkwood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.